See related research by Guo *et al*., <http://breast-cancer-research.com/content/15/4/R70>

In a recent issue of *Breast Cancer Research*, Guo and colleagues provided mechanistic evidence supporting the role for microRNA (miR)-510 as a novel oncomir playing a pivotal role in human breast cancer via regulation of expression of peroxiredoxin 1 \[[@B1]\]. Their study follows the original observation of elevated miR-510 expression in human breast tumor samples described by Findlay and colleagues in 2008 \[[@B2]\].

To acquire a deeper insight into the potential role of miR-510 in human breast cancer, we carried out an *in silico* analysis of the miR-510 abundance in clinical breast cancer samples using three independent publically available datasets (described in Additional file [1](#S1){ref-type="supplementary-material"}). Conspicuously, we have found that expression of miR-510 was virtually nonexistent in clinical sample sets (Dataset 1 \[[@B3]\] and Dataset 2 \[[@B4]\]). Only seven out of 473 clinical breast cancer specimens altogether demonstrated the miR-510 miRNA-Seq reads (Figure [1](#F1){ref-type="fig"}A,B, left), all of which could be attributed to a very low spectrum of the whole expression range of all miRNAs expressed in the respective datasets (Figure [1](#F1){ref-type="fig"}A,B, right). Analysis of the same kind carried out in 11 normal tissue samples (included in Dataset 2 \[[@B4]\]) revealed one sample expressing a low level of the miR-510 gene (Figure [1](#F1){ref-type="fig"}C). Similarly, one out of six breast cancer cell lines (included in Dataset 2) showed detectable expression of miR-510 (Figure [1](#F1){ref-type="fig"}D).

![**Overview of miR-510 expression in clinical breast cancer samples, normal breast tissues and six breast cancer cell lines using miRNA-Seq experimental results from two independent studies.** MicroRNA (miR)-510 expression from **(A)** Cancer Genome Atlas Network (Dataset 1 \[[@B3]\]) and **(B-D)** Farazi and colleagues (Dataset 2 \[[@B4]\]). Right: expression levels recorded for the miR-510-positive cases (red bars) in the context of the entire expression distribution of miRNA in the respective parts of the datasets.](bcr3624-1){#F1}

Analysis of an independent dataset (Dataset 3 \[[@B5]\]) showed expression of miR-510 in a substantial number of cases studied. One should, however, consider that, similar to the previously mentioned miRNA-Seq experiments, the expression of miR-510 in Dataset 3 could be attributed to the very low spectrum of the expression range (Figure [2](#F2){ref-type="fig"}A), and consider that microarray results are by their nature characterized by a very modest signal-to-noise separation, resulting in a low estimation confidence for the low readouts. Nevertheless, we did attempt to assess whether stratification of Dataset 3 by the median expression signal of miR-510 would correlate with the disease-free survival time (Figure [2](#F2){ref-type="fig"}B). Results of the analysis revealed that, although the higher strata of miR-510 expression showed a tendency to correlate with slightly worse disease-free survival times (Figure [2](#F2){ref-type="fig"}B), the correlation did not reach statistical significance (*P* = 1.88 × 10^−1^).

![**miR-510 expression signal derived from Agilent 4 × 44 K microarray dataset by Enerly and colleagues (Dataset 3**\[[@B5]\]**). (A)** MicroRNA (miR)-510 expression (red bars) presented against the expression signal distribution of the whole dataset. **(B)** Cox proportional hazard model of survival analysis of the groups stratified by the median value of the miR-510 expression signal. Note: two miR-510-positive cases did not have accompanying survival data assigned, hence the difference in number of cases shown in (A) and (B).](bcr3624-2){#F2}

Considering our observations and acknowledging the high clarity of mechanistic observations by Guo and colleagues \[[@B1]\], we assume that miR-510 ought to be further evaluated in human cancer types other than breast cancer, especially those in which peroxiredoxin 1 seems to play a role.
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